1. Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Issue 6 (29th November 2018) Authors: Goedeke, Leigh; Bates, Jamie; Vatner, Daniel F.; Perry, Rachel J.; Wang, Ting; Ramirez, Ricardo; Li, Li; Ellis, Matthew W.; Zhang, Dongyan; Wong, Kari E.; Beysen, Carine; Cline, Gary W.; Ray, Adrian S.; Shulman, Gerald I. Journal: Hepatology Issue: Volume 68:Issue 6(2018) Page Start: 2197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Issue 9 (23rd June 2022) Authors: Vijayakumar, Archana; Okesli‐Armlovich, Ayse; Wang, Ting; Olson, Isabel; Seung, Minji; Kusam, Saritha; Hollenback, David; Mahadevan, Sangeetha; Marchand, Bruno; Toteva, Maria; Breckenridge, David G.; Trevaskis, James L.; Bates, Jamie Journal: Hepatology communications Issue: Volume 6:Issue 9(2022) Page Start: 2298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Emerging characterization of the tumor-restraining subset of CAFs. Issue 9 (2022) Authors: Bates, Jamie Journal: Immuno-oncology insights Issue: Volume 3:Issue 9(2022) Page Start: 423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗